

- Dolutegravir (DTG) is the only second-generation integrase strand transfer inhibitor to receive FDA approval, and is approved for use in antiretroviral therapy (ART)-naïve and experienced adults and adolescents >12 years weighing at least 40 kg.
- In ART-naïve and experienced patients without prior integrase strand transfer inhibitors (INSTI) treatment, DTG is a potent, well-tolerated drug with the advantage of daily dosing.
- DTG has a high barrier to resistance with little cross-resistance to first-generation INSTI's, although in INSTI-experienced patients it should be dosed twice daily.
- In clinical trials, DTG + abacavir (ABC)/lamivudine (3TC) was superior to the fixed-dose combination emtricitabine (FTC)/ tenofovir (TDF)/ efavirenz (EFV), and a fixed-dose combination of ABC/3TC/DTG is being formulated.
- Newer formulations include a long-acting injectable nanosuspension, GSK1265744LA, with potential for monthly to quarterly dosing in prevention and treatment of HIV infection.

This summary slide represents the opinions of the authors. This review was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).